Genmab

Historical price data

Founded in 1999, Genmab's mission is to improve the lives of patients through innovative antibody therapeutics. The company has achieved remarkable success with its partnered assets, DARZALEX® and KESIMPTA®, which have become multi-billion dollar therapies, validating its scientific approach. Its strategy combines advancing a deep, wholly-owned clinical pipeline with high-value collaborations, funded by substantial royalty revenue. This hybrid model positions Genmab to sustainably capture value from both its platform innovation and direct drug development.

Genmab's core platforms include DuoBody® for creating bispecific antibodies, HexaBody® for enhancing antibody effector function, and the combined DuoHexaBody® platform, enabling the development of differentiated antibody therapeutics with novel mechanisms of action.